SCHEMBL3014700

SCHEMBL3014700

COc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccccc3Cl)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
LMNA P02545 4/20 0.52
ALDH1A1 P00352 4/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 2/20 0.52
RECQL P46063 2/20 0.48
USP2 O75604 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 3/20 0.48
AR P10275 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CHRM4 P08173 2/20 0.44
GAA P10253 2/20 0.44
GBA1 P04062 2/20 0.44
KDM1A O60341 1/20 0.43
TSHR P16473 1/20 0.43
FAAH O00519 1/20 0.43
EPHX2 P34913 1/20 0.43
REV1 Q9UBZ9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012617 0.93 LMNA (0.52) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3002844 0.90 LMNA (0.48) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3010342 0.90 MAPT (0.48) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3011256 0.89 MAPT (0.51) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3006754 0.89 REV1 (0.56) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3019066 0.89 AR (0.54) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3008115 0.89 ALDH1A1 (0.51) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3006453 0.89 MAPT (0.47) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3007932 0.88 MAPT (0.56) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3016689 0.88 TP53 (0.48) MAPTLMNAALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.